Diphtheria toxoid, haemophilus influenza type b, hepatitis b antigen, pertussis toxoid (Infanrix Hexa)
Diphtheria toxoid, haemophilus influenza type b, hepatitis b antigen, pertussis toxoid
Glaxosmithkline South Africa (Pty) Limited
Registration
- Applicant
- Glaxosmithkline South Africa (Pty) Limited
- Certificate holder
- Glaxosmithkline South Africa (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Infanrix hexa EACH 0,5 ml DOSE CONTAINS DIPHTHERIA TOXOID 30,0 iu HAEMOPHILUS INFLUENZA TYPE B 10,0 ug HEPATITIS B ANTIGEN 10,0 ug PERTUSSIS TOXOID 25,0 ug POLIO VIRUS TYPE 1 40,0 du POLIO VIRUS TYPE 2 8,0 du POLIO VIRUS TYPE 3 | 0,5 ml)Capsules, powder for oral suspension | 36034736/30.1/0347Approved 28 November 2017 | Registered | Not determined | PIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.